In this paper, we present a focused investigation into the formulation strategies employed to enhance the PK profiles of two distinct anti-cancer agents as follows: G7883, which is targeted for TEAD, and G6893, which is targeted for HPK1, each targeting unique signaling pathways. The gene discussed is MAP4K1; the disease is cancer.